Author:
Liu Chun-Yu,Tseng Ling-Ming,Su Jung-Chen,Chang Kung-Chi,Chu Pei-Yi,Tai Wei-Tien,Shiau Chung-Wai,Chen Kuen-Feng
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Alvarez RH, Valero V, Hortobagyi GN: Emerging targeted therapies for breast cancer.
J Clin Oncol 2010, 28:3366–3379.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK: SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute; 2011.
http://seer.cancer.gov/csr/1975_2008/
, based on November 2010 SEER data submission, posted to the SEER web site
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
J Clin Oncol 2002, 20:719–726.
4. Bromberg J: Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development.
Breast Cancer Res 2000, 2:86–90.
5. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.
Clin Cancer Res 2006, 12:20–28.
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献